Updated
The most significant concentration Arcutis Biotherapeutics discloses is ZORYVE franchise, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Arcutis Biotherapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our current product candidates.'”
“10-K Item 1: 'we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications'”
The company's concentration profile is defined by two reinforcing high-share exposures: a commercial-product dependency on a single franchise and a supply-side dependency on a single licensing counterparty. The business depends on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of its current product candidates, a high-share product concentration with a mixed character. The commercial ZORYVE franchise is both structural — it is the deliberate focus of the company's commercialization build-out — and dependency-like, because the entire revenue base rests on this single franchise's continued prescription growth, reimbursement stability, and competitive positioning. A setback for any ZORYVE product would directly impair the company's financial profile. Compounding this, the company's access to its core active ingredient is tied to a licensing agreement with AstraZeneca for exclusive worldwide rights to roflumilast as a topical product in humans for dermatological indications. This is a high-share supplier-type dependency: the company does not own the compound outright but holds a license, making the AstraZeneca relationship a foundational input. Any dispute, renegotiation, or adverse event affecting the licensing arrangement would threaten the company's ability to continue manufacturing and commercializing its products. Together, the two exposures create a layered dependency: commercial success depends on a single franchised molecule whose supply rights flow through a single licensor. Monitoring the AstraZeneca licensing relationship alongside ZORYVE market performance are the primary watch items for this concentration profile.
For the engine’s reasoning on ARQT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ARQT● | Arcutis Biotherapeutics, Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.